Cargando…

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa

INTRODUCTION: Dolutegravir has replaced efavirenz in most low‐ and middle‐income countries, due to better tolerability and formidable resistance profile, but dolutegravir side effects suggest alternatives are needed. We evaluated doravirine resistance in South Africa as a first step to assess whethe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steegen, Kim, Moorhouse, Michelle, Wensing, Annemarie MJ, Venter, Willem DF, Hans, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094661/ https://www.ncbi.nlm.nih.gov/pubmed/33943000 http://dx.doi.org/10.1002/jia2.25706

Ejemplares similares

Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes
por: Moorhouse, Michelle, et al.
Publicado: (2019)

Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory
por: Hans, Lucia, et al.
Publicado: (2021)

Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study
por: Hermans, Lucas E., et al.
Publicado: (2020)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

What is the role of CD4 count in a large public health antiretroviral programme?
por: Moorhouse, Michelle, et al.
Publicado: (2016)

Who is seeking antiretroviral treatment for HIV now? Characteristics of patients presenting in Kenya and South Africa in 2017‐2018
por: Brennan, Alana T, et al.
Publicado: (2019)

Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa
por: Brennan, Alana T, et al.
Publicado: (2023)

Profile of presentation of HIV-positive patients to an emergency department in Johannesburg, South Africa
por: Laher, Abdullah E., et al.
Publicado: (2021)

Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial
por: Venter, Willem D. F., et al.
Publicado: (2017)

Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa
por: Tomson, Anastacia, et al.
Publicado: (2021)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Retention in care and viral suppression after same‐day ART initiation: One‐year outcomes of the SLATE I and II individually randomized clinical trials in South Africa
por: Maskew, Mhairi, et al.
Publicado: (2021)

Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: a retrospective cohort data analysis
por: Gumede, Siphamandla Bonga, et al.
Publicado: (2022)

Changes in weight and BMI with first-line doravirine-based therapy
por: Orkin, Chloe, et al.
Publicado: (2021)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
por: Zizioli, Daniela, et al.
Publicado: (2023)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development
por: Martin, Elizabeth Anne, et al.
Publicado: (2020)

High-Level Cross-Resistance to Didanosine Observed in South African Children Failing an Abacavir- or Stavudine-Based 1(st)-Line Regimen
por: Steegen, Kim, et al.
Publicado: (2014)

Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second‐line ART
por: Hermans, Lucas E, et al.
Publicado: (2020)

Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
por: Chandiwana, Nomathemba C., et al.
Publicado: (2021)

Southern African HIV Clinicians Society guidelines for harm reduction
por: Scheibe, Andrew, et al.
Publicado: (2020)

Timing, rates, and causes of death in a large South African tuberculosis programme
por: Field, Nigel, et al.
Publicado: (2014)

Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
por: Rock, Alexander E, et al.
Publicado: (2020)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

A descriptive analysis of the role of a WhatsApp clinical discussion group as a forum for continuing medical education in the management of complicated HIV and TB clinical cases in a group of doctors in the Eastern Cape, South Africa
por: Woods, Joana, et al.
Publicado: (2019)

HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project
por: Eakle, Robyn, et al.
Publicado: (2017)

AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa
por: Chu, Kathryn M, et al.
Publicado: (2010)

Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa
por: Roozen, Geert V. T., et al.
Publicado: (2021)

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
por: Molina, Jean-Michel, et al.
Publicado: (2022)

Clinical outcomes after first‐line HIV treatment failure in South Africa: the next cascade of care
por: Iwuji, CC, et al.
Publicado: (2020)

The integration of occupational- and household-based chronic stress among South African women employed as public hospital nurses
por: Cohen, Jennifer, et al.
Publicado: (2020)

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa
por: Brennan, Alana T., et al.
Publicado: (2023)

545. Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients
por: Hwang, Carey, et al.
Publicado: (2018)

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2023)

2548. Pharmacokinetic Analysis of Co-Administering Doravirine, Tenofovir Disoproxil Fumarate, Estradiol, and Spironolactone
por: Lam, Kevin, et al.
Publicado: (2023)

The contribution of family physicians to surgical capacity at district hospitals in South Africa
por: Hendriks, Hans, et al.
Publicado: (2021)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3p3rndnhd9jeukuj6sm4jtv5mc